Physician profile
Sunil Rohatgi
NPI 1912351727
$5,701.10
in general payments reported to CMS, 2019-2025
50 companies · $2,355 in 2025
The $2,355 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2022: $65.58 · 2023: $1,025 · 2024: $2,132 · 2025: $2,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,087 · Education: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,087.13 |
| Education | $425.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $633.93 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $523.00 | 2023-2025 | |
| Janssen Biotech, INC. | $329.52 | 2024-2025 | Rybrevant, Carvykti, Tecvayli |
| Daiichi Sankyo INC. | $317.42 | 2022-2025 | Enhertu, Vanflyta, Datroway |
| Incyte Corporation | $302.84 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $215.41 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $210.90 | 2023-2025 | Calquence, Enhertu, Imfinzi |
| Blueprint Medicines Corporation | $190.99 | 2023-2024 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $183.55 | 2020-2025 | Opdivo, Augtyro |
| Celgene Corporation | $174.01 | 2024-2025 | Reblozyl, Opdivo, Pomalyst |
| Abbvie INC. | $163.06 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $161.09 | 2024-2025 | |
| Astellas Pharma US INC | $155.54 | 2023-2025 | Padcev, Vyloy |
| Genentech USA, INC. | $139.30 | 2023-2024 | Tecentriq, Phesgo, Perjeta |
| Gilead Sciences, INC. | $132.01 | 2024-2025 | Trodelvy |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $129.14 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Puma Biotechnology, INC. | $125.00 | 2025 | |
| Glaxosmithkline, LLC. | $124.16 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Adaptive Biotechnologies Corporation | $112.10 | 2025 | Clonoseq |
| Eisai INC. | $104.07 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.08 | 2023-2025 | Iclusig, Vpriv, Ninlaro |
| Merck Sharp & Dohme LLC | $80.63 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Sobi, INC | $78.02 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Seagen INC. | $69.00 | 2025 | |
| Adc Therapeutics America, INC. | $65.66 | 2023-2025 | |
| Coherus Oncology, INC. | $63.76 | 2024 | |
| Stemline Therapeutics INC. | $60.60 | 2023-2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $58.83 | 2025 | Libtayo |
| Beone Medicines USA, INC. | $56.19 | 2025 | Tevimbra, Brukinsa |
| Aveo Pharmaceuticals, INC. | $44.13 | 2023-2024 | Fotivda |
| Sumitomo Pharma America, INC. | $43.54 | 2025 | Orgovyx |
| Lilly USA, LLC | $41.41 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.28 | 2025 | |
| Emd Serono, INC. | $40.18 | 2025 | |
| Shield Therapeutics INC | $37.20 | 2024 | |
| Dendreon Pharmaceuticals LLC | $34.90 | 2025 | Provenge |
| Amgen INC. | $30.59 | 2023 | Lumakras, Nplate, Neulasta |
| Kyowa Kirin, INC. | $29.10 | 2025 | |
| Pharmacosmos Therapeutics INC. | $27.99 | 2025 | Monoferric |
| Taiho Oncology, INC. | $26.30 | 2025 | |
| Pharmaessentia USA Corporation | $25.09 | 2025 | Besremi |
| Geron Corporation | $24.36 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $23.18 | 2025 | Enjaymo |
| Myriad Genetic Laboratories, INC. | $22.76 | 2023 | Myrisk |
| Karyopharm Therapeutics INC. | $19.15 | 2023 | Xpovio |
| Corcept Therapeutics | $17.83 | 2025 | Korlym |
| Novocure INC. | $16.93 | 2025 | Optune Lua (Novottf-200t) |
| Teleflex LLC | $16.67 | 2025 | Arrow |
| Verity Pharmaceuticals INC. | $14.71 | 2024 | Trelstar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Rohatgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.